Anna Maria Fulghesu

List of Publications by Citations

Source: https://exaly.com/author-pdf/1493126/anna-maria-fulghesu-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15 35 921 30 h-index g-index citations papers 998 3.1 3.1 37 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
35	A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. <i>Fertility and Sterility</i> , 2001 , 76, 326-31	4.8	120
34	Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. <i>Metabolism: Clinical and Experimental</i> , 1999 , 48, 167-72	12.7	98
33	N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2002 , 77, 1128-35	4.8	92
32	Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. <i>Human Reproduction</i> , 1990 , 5, 143-9	5.7	54
31	Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. <i>Fertility and Sterility</i> , 1992 , 58, 296-301	4.8	51
30	Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E204-8	5.6	44
29	Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 1995 , 63, 1195-9	4.8	44
28	Effect of pituitary adenylate cyclase-activating peptide on meiotic maturation in follicle-enclosed, cumulus-enclosed, and denuded rat oocytes. <i>Biology of Reproduction</i> , 1997 , 57, 1074-9	3.9	43
27	Effect of maternal carbohydrate metabolism on fetal growth. <i>Obstetrics and Gynecology</i> , 1998 , 92, 8-12	4.9	40
26	Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. <i>Fertility and Sterility</i> , 2010 , 93, 2303-10	4.8	39
25	Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. <i>Fertility and Sterility</i> , 1994 , 62, 35-41	4.8	36
24	Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006 , 86, 398-404	4.8	29
23	Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. <i>Fertility and Sterility</i> , 1995 , 64, 703-8	3 ^{4.8}	25
22	Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. <i>Metabolism: Clinical and Experimental</i> , 1998 , 47, 158-62	12.7	21
21	Hirsutism and hyperandrogenism associated with hyperreactio luteinalis in a singleton pregnancy: a case report. <i>Gynecological Endocrinology</i> , 2007 , 23, 248-51	2.4	21
20	Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 1997 , 67, 34-9	4.8	14
19	Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment. <i>Hormone Research in Paediatrics</i> , 2001 , 55, 224-8	3.3	13

(2018-2001)

18	Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 483-90	5.2	13
17	Diagnosis of metabolic disorders in women with polycystic ovary syndrome. <i>Obstetrical and Gynecological Survey</i> , 2008 , 63, 796-802	2.4	12
16	Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 1742-5	5.6	12
15	Evidence of a disturbance of the hypothalamic-pltuitary-adrenal axis in polycystic ovary syndrome: effect of naloxone. <i>Clinical Endocrinology</i> , 1996 , 45, 73-77	3.4	12
14	Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2015 , 103, 808-14	4.8	11
13	Comment on "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome". <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 297	4-5	10
12	The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome. <i>Gynecological Endocrinology</i> , 2011 , 27, 468-74	2.4	9
11	HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). <i>Gynecological Endocrinology</i> , 2020 , 36, 588-593	2.4	8
10	Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome. <i>Human Reproduction</i> , 1994 , 9, 2242-6	5.7	8
9	Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus. <i>Hormone Research in Paediatrics</i> , 1998 , 49, 263-8	3.3	7
8	Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 1999 , 71, 462-7	4.8	7
7	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome		7
6	Ovulation induction in young girls with menometrorragia: a safe and effective treatment. <i>Gynecological Endocrinology</i> , 2014 , 30, 117-20	2.4	6
5	Polycystic Ovarian Morphology in Normocyclic Non-hyperandrogenic Adolescents. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2021 , 34, 610-616	2	5
4	Urinary Metabolites Reveal Hyperinsulinemia and Insulin Resistance in Polycystic Ovarian Syndrome (PCOS). <i>Metabolites</i> , 2021 , 11,	5.6	4
3	Very low dose of flutamide in the treatment of hyperandrogenism. <i>Gynecological Endocrinology</i> , 2018 , 34, 394-398	2.4	4
2	Effect of luteal metoclopramide-induced hyperprolactinemia on pituitary and luteal responsiveness to gonadotropin-releasing hormone. <i>Hormone Research</i> , 1989 , 31, 169-74		1
1	Diagnosis of Polycystic Ovarian Syndrome in Adolescence 2018 , 143-159		1